Despite the significant breakthrough represented by autologous cell therapies in the field of cancer immunotherapy, challenges remain. Autologous cell therapies require bespoke manufacturing processes resulting in high costs, manufacturing failure in some patients and delay in availability of treatment.

Allogeneic cell therapies can address these issues using healthy donors and scaled-up manufacturing processes. However, several key challenges still need to be overcome such as avoiding GVHD and avoiding elimination by the host immune system.

Bringing together both immunotherapy and regenerative medicine leaders, the Allogeneic Cell Therapy Summit is focused on the clinical and commercial development of engineered allogeneic cell therapies with improved manufacturing and commercialization to benefit patients in need.